List of Excipients in Branded Drug FLUCYTOSINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cameron Pharmaceuticals LLC	FLUCYTOSINE	flucytosine	42494-339	D&C YELLOW NO. 10
Cameron Pharmaceuticals LLC	FLUCYTOSINE	flucytosine	42494-339	FD&C BLUE NO. 1
Cameron Pharmaceuticals LLC	FLUCYTOSINE	flucytosine	42494-339	FD&C YELLOW NO. 6
Cameron Pharmaceuticals LLC	FLUCYTOSINE	flucytosine	42494-339	FERROSOFERRIC OXIDE

Generic Drugs Containing FLUCYTOSINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	flucytosine	0054-0427	D&C YELLOW NO. 10
Hikma Pharmaceuticals USA Inc	flucytosine	0054-0427	FD&C BLUE NO. 1
Hikma Pharmaceuticals USA Inc	flucytosine	0054-0427	FD&C GREEN NO. 3
Hikma Pharmaceuticals USA Inc	flucytosine	0054-0427	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in FLUCYTOSINE?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
2	ANHYDROUS LACTOSE
9	D&C YELLOW NO. 10
12	FD&C BLUE NO. 1

Flucytosine Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Flucytosine is an old, off-patent antifungal with high clinical value in cryptococcal meningitis and invasive Candida infections. Its commercial weakness is formulation and access, not active-ingredient protection. The principal opportunities are reliable 250 mg and 500 mg oral products, pediatric and dysphagia-friendly presentations, improved global supply, and formulations that support combination therapy with amphotericin B.

The strongest product strategy is a low-risk immediate-release capsule or tablet using well-established excipients, backed by tight control of dissolution, content uniformity, moisture exposure, and renal-dose administration. A differentiated pediatric formulation could create more value than an unnecessarily complex modified-release product.

What is flucytosine and how is it used?

Flucytosine, also called 5-fluorocytosine or 5-FC, is an oral antimetabolite antifungal. It is converted intracellularly to fluorouracil metabolites that inhibit fungal RNA and DNA synthesis. The drug is used primarily with amphotericin B for cryptococcal meningitis and selected serious Candida infections.

The FDA-approved product historically marketed as Ancobon contains flucytosine in 250 mg and 500 mg capsules. The labeled adult dose is generally 50 to 150 mg/kg/day, divided into four administrations at approximately six-hour intervals, with dosage reduction required for impaired renal function (FDA, 2023a).

Attribute	Flucytosine profile
Active ingredient	Flucytosine, 5-fluorocytosine
Main dosage form	Immediate-release oral capsule
Common strengths	250 mg and 500 mg
Key indications	Cryptococcal meningitis; serious Candida infections
Typical adult dosing	50-150 mg/kg/day in four divided doses
Main elimination route	Renal excretion
Key toxicity concern	Bone-marrow suppression and hepatotoxicity
Main combination partner	Amphotericin B
FDA regulatory status	Approved oral capsule product and generic pathway
Major commercial constraint	High cost, limited availability, and low-volume demand
Primary formulation challenge	High total daily dose with narrow therapeutic-management requirements

Flucytosine has high oral bioavailability, commonly reported at approximately 80% to 90%. Its pharmacokinetics are strongly affected by kidney function, making reliable dose delivery and renal-adjustment support more commercially relevant than extended-release technology (Perfect et al., 2010).

What excipients are used in flucytosine capsules?

Published product labels identify conventional capsule excipients, but the exact composition depends on the manufacturer and market. The Ancobon label lists inactive ingredients associated with the capsule formulation, including croscarmellose sodium, magnesium stearate, povidone, sodium lauryl sulfate, colloidal silicon dioxide, and capsule-shell components such as gelatin, titanium dioxide, and colorants (FDA, 2023a).

A generic manufacturer may use a different excipient system if it demonstrates pharmaceutical equivalence and bioequivalence.

Excipient function	Suitable strategy for flucytosine	Commercial rationale
Diluent or filler	Microcrystalline cellulose, lactose, or another qualified filler	Supports capsule fill weight and content uniformity
Disintegrant	Croscarmellose sodium or crospovidone	Promotes rapid release from a high-dose capsule
Binder	Povidone or equivalent dry binder	Supports granule integrity where wet or dry granulation is used
Glidant	Colloidal silicon dioxide	Improves powder flow and automated filling
Lubricant	Magnesium stearate at controlled concentration	Supports manufacturing without excessive dissolution delay
Surfactant	Sodium lauryl sulfate or another qualified wetting agent	Can improve wetting of hydrophobic or poorly flowing blends
Capsule shell	Gelatin or hypromellose	Enables conventional and vegetarian capsule options
Colorant	Market-specific permitted colorants	Supports identification and product differentiation
Moisture-control material	Protective blister, high-barrier bottle, or desiccant system	Protects long-term stability and supply-chain quality

The principal risk is not excipient toxicity. It is excessive lubrication, poor powder flow, segregation, capsule-weight variability, or delayed dissolution. A high-dose product leaves limited room for inactive ingredients, so the formulation must balance manufacturability against capsule size and patient burden.

Which excipients are most commercially attractive?

Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, povidone, and magnesium stearate are commercially attractive because they have extensive regulatory histories and broad supplier availability. They also reduce the need for novel excipient justification.

A manufacturer seeking a differentiated product could use:

• A hard-gelatin capsule with a high-barrier blister for standard adult use.
• A hypromellose capsule for customers seeking a non-gelatin shell.
• A powder-for-reconstitution product for pediatric or dysphagia populations.
• A dispersible tablet containing conventional disintegrant and wetting systems.
• A multiparticulate formulation that allows flexible dose measurement.

Novel excipients would add regulatory and supply-chain complexity without a clear clinical advantage. The drug’s immediate-release pharmacology and high total dose make conventional excipients the more defensible commercial choice.

What formulation patents protect flucytosine products?

Flucytosine’s original active-ingredient protection is expired. The molecule was developed decades ago, and modern products are generally exposed to generic competition. The commercial patent opportunity therefore lies in formulation, manufacturing, packaging, pediatric delivery, or combination-product claims rather than basic composition-of-matter protection.

Potential patentable categories include:

1. Stable powder-for-reconstitution systems.
2. Taste-masked liquid or dispersible formulations.
3. Unit-dose products for renal-adjusted administration.
4. Specific moisture-protective packaging configurations.
5. Combination dosage forms containing flucytosine and an antifungal partner.
6. Manufacturing processes that improve content uniformity or reduce degradation.
7. Pediatric dosage forms with defined particle size, dosing accuracy, or reconstitution stability.

A patent must provide a measurable technical advantage. A claim covering an ordinary capsule with routine excipients would face substantial obviousness and enablement risks.

What is the Orange Book status of flucytosine?

The FDA Orange Book is the principal U.S. reference for approved prescription drug products, therapeutic-equivalence evaluations, and listed patent or exclusivity information. Flucytosine’s market position is consistent with an old, genericized oral product rather than a product protected by current, material exclusivity (FDA, 2024).

Because listing status can change by manufacturer and product presentation, commercial diligence should distinguish among:

• The discontinued or legacy branded Ancobon product.
• Currently marketed abbreviated new drug applications.
• FDA-approved strengths and package configurations.
• Any listed patents associated with a specific current product.
• National Drug Code activity and actual commercial availability.

No meaningful U.S. market barrier is expected from an unexpired flucytosine composition patent. The relevant barriers are manufacturing validation, bioequivalence, supply reliability, and market access.

When does flucytosine lose exclusivity?

Flucytosine lost meaningful market exclusivity many years ago. The active ingredient is off patent, and any original regulatory exclusivity has expired. A new sponsor would need to create protection through a qualifying formulation, manufacturing, pediatric, or combination invention.

Exclusivity category	Current commercial relevance
Composition-of-matter patent	Expired
Original product exclusivity	Expired
Standard generic entry	Generally available in principle
Formulation patent	Possible only for a technically distinct product
Method-of-use patent	Limited opportunity because core uses are established
Orphan-drug exclusivity	Could arise only from a new qualifying development program
Pediatric exclusivity	Not an automatic current barrier; would require a qualifying FDA program
Data exclusivity	No material current barrier for the established drug

The opportunity is therefore a regulated product-development strategy, not recovery of an old exclusivity position.

What excipient strategy best fits flucytosine?

Immediate-release capsules for adult treatment

The base commercial product should remain an immediate-release capsule. Flucytosine is dosed four times daily and is used in critically ill patients whose exposure must be managed around renal function. A sustained-release formulation could complicate toxicity management and would require extensive clinical justification.

The preferred design targets are:

• Rapid and consistent dissolution.
• High drug loading.
• Low capsule count.
• Robust content uniformity.
• Low sensitivity to lubricant concentration.
• Stability under high humidity and temperature excursions.
• Compatibility with automated filling and high-barrier packaging.

The 500 mg strength minimizes capsule burden, while the 250 mg strength supports weight-based and renal-adjusted dosing.

Pediatric and dysphagia formulations

The clearest formulation gap is a flexible oral presentation. Children, critically ill patients, and patients with swallowing difficulty may not reliably use hard capsules. A powder for reconstitution, dispersible tablet, or oral suspension could improve administration.

A pediatric product would need data on:

• Reconstitution volume.
• In-use stability.
• Dose uniformity after shaking.
• Syringe withdrawal accuracy.
• Palatability and taste masking.
• Compatibility with enteral feeding tubes.
• Microbial control for aqueous products.
• Renal-dose flexibility.

Taste masking is commercially relevant because flucytosine has an unpleasant taste profile when administered as a liquid. A polymer coating, ion-exchange approach, or multiparticulate system could support palatability, but each increases development and manufacturing complexity.

Compounded oral solutions

Hospitals may compound oral liquids when commercial capsules are unavailable or unsuitable. A validated commercial liquid could compete with informal compounding by providing reproducible concentration, stability, labeling, and dosing instructions.

The commercial risk is limited volume. A liquid may also carry shorter in-use dating and higher distribution costs than capsules. The strongest target market is hospital and pediatric use rather than broad outpatient dispensing.

What regulatory pathway applies to a new flucytosine product?

A conventional generic capsule would generally use an abbreviated new drug application under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence, bioequivalence, manufacturing quality, and stability.

A materially different formulation could require a 505(b)(2) application if it relies partly on the existing flucytosine product or published data while introducing a new dosage form, route, strength, or formulation.

Product concept	Likely U.S. pathway	Main development issue
250 mg generic capsule	ANDA	Bioequivalence and manufacturing controls
500 mg generic capsule	ANDA	Bioequivalence, content uniformity, supply scale
New dispersible tablet	ANDA or 505(b)(2), depending on formulation and reliance	In vitro release, usability, possibly clinical bridging
Oral suspension	Usually 505(b)(2) if materially different	Stability, taste, dosing accuracy, microbial control
Fixed-dose amphotericin B combination	Likely 505(b)(2) or new drug pathway	Drug-drug compatibility, dose flexibility, safety
Novel delivery system	505(b)(2) or full NDA depending on reliance	Clinical exposure and risk-benefit evidence

Flucytosine requires particular attention to renal dosing and drug exposure. A formulation that changes absorption or peak concentrations could create safety concerns even if total exposure appears similar.

Which companies are challenging flucytosine and how competitive is the market?

The principal competitive threat is generic entry, not a branded innovator. Market participation has historically been constrained by low demand, limited suppliers, and high prices relative to the drug’s age. In the United States, access has also been affected by product availability and supplier continuity.

Competition comes from:

• Generic capsule manufacturers.
• Specialty infectious-disease suppliers.
• International manufacturers serving low- and middle-income markets.
• Hospital pharmacies and compounding facilities.
• Alternative antifungal regimens when flucytosine is unavailable.

The product has a small addressable market compared with common antifungals, but treatment guidelines continue to support flucytosine as part of preferred or important combination therapy for cryptococcal meningitis. The World Health Organization has identified access to flucytosine and amphotericin B as a priority in cryptococcal disease management (World Health Organization, 2022).

What companies or partnerships could create value?

A sponsor could pursue:

• Licensing from an established active pharmaceutical ingredient producer.
• Contract manufacturing with a specialty oral-solid-dose facility.
• Procurement agreements with global-health organizations.
• Regional distribution partnerships in Africa, Asia, and Latin America.
• A hospital-focused supply contract guaranteeing minimum inventory.
• A co-pack or coordinated-treatment package with amphotericin B.

A fixed-dose combination may improve adherence but could reduce flexibility because amphotericin B and flucytosine dosing, administration, and formulation requirements differ. A coordinated co-pack is more commercially practical than a single combined dosage form.

What generic launch risks exist for flucytosine?

A generic launch can occur without a major patent obstacle, but commercial execution remains difficult.

Risk	Effect on launch
Small patient population	Limits manufacturing scale and return on investment
Low hospital inventory	Creates stockout risk and emergency procurement
Renal-dose complexity	Raises medication-use and labeling demands
High capsule burden	Reduces usability, especially in pediatrics
API supply concentration	Increases dependence on limited qualified suppliers
Stability failures	Can cause recalls or restricted distribution
Price competition	Can erode margins quickly
Low prescriber familiarity	Slows conversion to a new supplier
Combination-therapy dependence	Links demand to amphotericin B availability
Global procurement requirements	May require additional quality and prequalification work

A launch model based only on low generic price may be unattractive. A supply-assurance model with hospital contracts, emergency stock, and pediatric capability has stronger commercial logic.

How strong is the flucytosine patent estate?

The core patent estate is weak because the active ingredient and established uses are old. Patent strength could be moderate for a genuinely differentiated formulation that solves a documented problem, such as pediatric dosing or liquid stability.

Patent category	Expected strength
Flucytosine composition of matter	Very weak or expired
Conventional capsule formulation	Weak
Routine excipient substitution	Weak
Stable oral suspension	Moderate if supported by comparative data
Taste-masked pediatric multiparticulates	Moderate
Tube-compatible dispersible product	Moderate if technically specific
New combination product	Variable and dependent on clinical differentiation
Manufacturing process	Moderate if it improves a critical quality attribute
Packaging and moisture protection	Usually limited unless narrowly technical

The strongest claims would link a defined excipient system to a measurable result, such as improved stability, reduced degradation, controlled reconstitution, or reproducible dosing. Broad claims covering standard pharmaceutical excipients would be vulnerable to prior art and obviousness attacks.

What patent litigation and Paragraph IV risks affect flucytosine?

No major, current flucytosine patent litigation is a central market factor. A new formulation could generate Paragraph IV risk if it is submitted against an innovator product with listed patents, but a conventional generic capsule would generally face a much lower patent challenge profile because the original protection has expired.

A sponsor pursuing a 505(b)(2) product should assess:

• Any patents listed for the reference product.
• Method-of-use claims relevant to the proposed label.
• Formulation or dosage-form patents.
• Patent-term adjustment and pediatric extensions.
• Potential declaratory-judgment exposure.
• Carve-out opportunities for non-protected indications.

The legal value of a flucytosine product is more likely to come from regulatory exclusivity attached to a new formulation or indication than from enforcement of old molecule patents.

What geographic markets offer the best commercial opportunities?

The most significant unmet need is in regions where cryptococcal meningitis is common and access to antifungal medicines is inconsistent. Sub-Saharan Africa has particular relevance because HIV-associated cryptococcal disease remains a major cause of morbidity and mortality. WHO guidelines support access to flucytosine-based treatment where clinically appropriate (World Health Organization, 2022).

Market	Opportunity	Main constraint
United States	Reliable generic supply and pediatric presentation	Small volume and reimbursement pressure
Europe	Hospital procurement and established infectious-disease use	National pricing and tender systems
Sub-Saharan Africa	Large public-health need	Procurement budgets, distribution, and registration
India	Manufacturing and export platform	Price competition and regulatory variation
Southeast Asia	Regional supply and hospital demand	Fragmented registration requirements
Latin America	Improved access and local distribution	Tender-based pricing and registration complexity

A dual-market strategy could use a conventional high-barrier capsule for regulated markets and a lower-cost, quality-assured product for global-health procurement. Manufacturing economics would depend heavily on API cost, minimum batch size, and the ability to maintain continuous supply.

What revenue exposure can a flucytosine product generate?

Public revenue estimates for flucytosine are limited because sales are fragmented across markets, suppliers, hospital channels, and procurement contracts. It is not a mass-market antifungal. Revenue depends more on price, supply reliability, and contract access than on prescription volume.

The commercial model is strongest where a supplier can combine:

• A 250 mg and 500 mg capsule portfolio.
• A pediatric or liquid presentation.
• Hospital and public-health contracts.
• Reliable API sourcing.
• Global regulatory registrations.
• Emergency inventory capability.
• Competitive but sustainable pricing.

A formulation-only strategy without distribution and procurement infrastructure may capture limited value. The commercial opportunity is a specialty-access platform, not a high-volume generic.

Key Takeaways

• Flucytosine is an old, off-patent antifungal with no meaningful composition-of-matter exclusivity.
• Conventional immediate-release capsules remain the lowest-risk formulation.
• The most relevant excipients are standard materials such as croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, and capsule-shell materials.
• Pediatric, dysphagia-friendly, tube-compatible, and liquid formulations offer the clearest differentiation.
• A 250 mg/500 mg strength portfolio is important because dosing depends on body weight and renal function.
• The largest commercial barriers are supply reliability, low market volume, API sourcing, and procurement access.
• Formulation patents could be viable only when tied to measurable stability, palatability, dosing, or manufacturing improvements.
• A 505(j) pathway is likely for a conventional generic capsule; a materially different dosage form may require 505(b)(2).
• No major current patent litigation is the primary market risk.
• Global-health procurement and hospital supply contracts are more important than traditional branded promotion.

FAQs

Can flucytosine be formulated as an oral suspension?

Yes. An oral suspension could address pediatric and swallowing-related needs, but development must establish chemical and microbiological stability, dose uniformity, palatability, and in-use storage conditions.

Is a fixed-dose flucytosine and amphotericin B product commercially feasible?

A single fixed-dose product would face major compatibility and dosing challenges. A coordinated co-pack is more practical because the two drugs have different dosage forms, administration requirements, and dose-adjustment considerations.

Are novel excipients necessary for a differentiated flucytosine product?

No. A differentiated product can use established excipients if it delivers a clear advantage in stability, taste masking, reconstitution, or dose flexibility. Novel excipients would increase regulatory burden.

Does renal impairment change the commercial formulation strategy?

Yes. Renal impairment requires dosage adjustment and monitoring, which favors flexible strengths, accurate dose measurement, and immediate-release delivery over prolonged-release systems.

Can flucytosine obtain new patent protection?

Potentially, but protection would need to cover a technically specific formulation, manufacturing process, pediatric delivery system, combination product, or other invention with evidence of a non-obvious performance advantage.

References

1. U.S. Food and Drug Administration. (2023a). Ancobon (flucytosine) capsules prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., Pappas, P. G., Powderly, W. G., Singh, N., Sobel, J. D., & Sorrell, T. C. (2010). Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 50(3), 291-322.

4. World Health Organization. (2022). Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. World Health Organization.

5. U.S. Food and Drug Administration. (2023b). Inactive ingredient database. FDA.